http://www.gotoper.com/publications/ajho/2017/2017october

October 2017


Chairman's Letter
Chairman’s Letter
Michael J. Hennessy, Sr
Chairman’s Letter
From the Editor
From the Editor
Debu Tripathy, MD
Breast Cancer
Controversies and Clinical Trials for DCIS: Margins and Active Surveillance
Henry M. Kuerer, MD, PhD, FACS
breast cancer
Controversies and Clinical Trials for DCIS: Margins and Active Surveillance
Henry M. Kuerer, MD, PhD, FACS
Controversies in HER2 Oncogene Testing: What Constitutes a True Positive Result in Patients With Breast Cancer?
Michael F. Press, MD, PhD; Yanling Ma, MD; Susan Groshen, PhD; Guido Sauter, MD, PhD; and Dennis J. Slamon, MD, PhD
Controversies in HER2 Oncogene Testing: What Constitutes a True Positive Result in Patients With Breast Cancer?
Controversies in HER2 Oncogene Testing: What Constitutes a True Positive Result in Patients With Breast Cancer?
Small Lymphocyatic Lymphoma
Case Report: SLL/CLL Associated With Paraneoplastic Hyperimmunoglobulinemia and Vasculitic Skin Lesions
Neil Nagovski, MD; Amanda Brahim, PharmD; Alina Khan, PharmD; and Marco Ruiz, MD
Bladder Cancer
Basic Concepts in Bladder Cancer Immunotherapy
J. Ryan Mark, MD; Jean Hoffman-Censits, MD; and Leonard G. Gomella, MD
Leukemia
Second-Generation Brutons Tyrosine Kinase Inhibitors
Sarmen Sarkissian, MD, and Susan M. O’Brien, MD
Chronic Lymphocytic Leukemia
Second-Generation Brutons Tyrosine Kinase Inhibitors
Sarmen Sarkissian, MD, and Susan M. O’Brien, MD
Second-Generation Brutons Tyrosine Kinase Inhibitors
CME
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase Deficiency
Rachael Grace, MD
Personalizing Medical Care for GEP-NETs